Quantumscape Corporation
-$425.39M- Market cap
- $523.07M
- Debt
- +$22.36M
- Cash
- −$970.81M
Capital structure 96% equity / 4% debt · EV / EBITDA 0.99x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: QS stock price vs ANIK: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ANIK's multiple
Needs Revenue / share.
Implied fair value · at QS's multiple
Needs QS P/S.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: QS FY 2025 (ended Dec 31, 2025) · ANIK FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 96% equity / 4% debt · EV / EBITDA 0.99x
Capital structure 100% equity / -0% debt · EV / Revenue 1.75x
ANIK carries the larger enterprise value at $197.18M against -$425.39M.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
QUANTUMSCAPE CORPORATION · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Anika Therapeutics, Inc. · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.02x
-0.00x
Net debt / EBITDA
Leverage against operating earnings
2.21x
34.65x
Cash and equivalents
Liquid reserves on the balance sheet
$970.81M
$81.17M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
$22.36M
-$149.00K
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.